{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:14:53Z","timestamp":1782951293513,"version":"3.54.5"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>We herein describe the case of a 52-year-old male patient who presented with fever, arthritis, and neutrophilic dermatosis in 2013 and subsequently experienced macrophage activation syndrome treated with high-dose glucocorticoid therapy. Due to the persistent symptoms refractory to several immunomodulatory and immunosuppressive (IS) drug therapies with dapsone, methotrexate, tacrolimus, infliximab (IFX), and tocilizumab (TCZ), he received prednisolone (PSL) \u226520\u2009mg\/day to suppress disease activity. In 2017, Epstein\u2013Barr virus (EBV)\u2013associated haemophagocytic lymphohistiocytosis (HLH) was diagnosed and initially treated with immunochemotherapy consisting of dexamethasone, cyclosporine (CyA), and etoposide (ET). Because of the suboptimal response to the initial therapy, cytoreduction therapy consisting of CHOP (combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and PSL) was administered. This regimen improved the EBV-associated HLH. Later, the patient\u2019s condition stabilised with methylprednisolone 1\u2009mg\/day and CyA 100\u2009mg\/day. In 2022, ubiquitylation-initiating E1 enzyme (UBA1) variant analysis using Sanger sequencing of peripheral blood leukocytes detected a previously reported somatic variant (NM_003334.3: c.118-1G&amp;gt;C), confirming the diagnosis of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. The clinical course in the present case suggested the possibility that CHOP could be a potential treatment option for VEXAS syndrome, in the pathophysiology of which the expansion of clones with UBA1 variant seems to play a pivotal role.<\/jats:p>","DOI":"10.1093\/mrcr\/rxad041","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T10:13:02Z","timestamp":1691403182000},"page":"199-204","source":"Crossref","is-referenced-by-count":10,"title":["Long-term remission of\u00a0VEXAS syndrome achieved by a single course of\u00a0CHOP therapy: A case report"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8724-6393","authenticated-orcid":false,"given":"Yuji","family":"Miyoshi","sequence":"first","affiliation":[{"name":"Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center , Tokyo, Japan"},{"name":"Department of Clinical Genomics, Tokyo Metropolitan Tama Medical Center , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayasu","family":"Kise","sequence":"additional","affiliation":[{"name":"Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Morita","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Jichi Medical University , Shimotsuke, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokyo Metropolitan Tama Medical Center , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Ichi","family":"Imadome","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Infections, National Center for Child Health and Development , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Tsuchida","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"},{"name":"Department of Human Genetics, Yokohama City University Graduate School of Medicine , Yokohama, Japan"},{"name":"Department of Rare Disease Genomics, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, Yokohama City University Graduate School of Medicine , Yokohama, Japan"},{"name":"Department of Rare Disease Genomics, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kirino","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomichi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, Yokohama City University Graduate School of Medicine , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Yokogawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"2023122911392047600_R1","first-page":"3591","article-title":"VEXAS syndrome","volume":"137","author":"Grayson","year":"2021","journal-title":"Blood"},{"key":"2023122911392047600_R2","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in\u00a0UBA1 and\u00a0severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"key":"2023122911392047600_R3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.678927","article-title":"Case report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome","volume":"12","author":"Staels","year":"2021","journal-title":"Front Immunol"},{"key":"2023122911392047600_R4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/mrcr\/rxac082","article-title":"Acute heart failure due to left common iliac arteriovenous fistula: a case of\u00a0VEXAS syndrome","volume":"7","author":"Yamaguchi","year":"2022","journal-title":"Mod Rheumatol Case Rep"},{"key":"2023122911392047600_R5","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2021-220089","article-title":"Pathogenic UBA1 variants associated with VEXAS syndrome in\u00a0Japanese patients with relapsing polychondritis","volume":"80","author":"Tsuchida","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023122911392047600_R6","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192262","article-title":"Rapid identification and\u00a0characterization of\u00a0infected cells in\u00a0blood during chronic active Epstein-Barr virus infection","volume":"217","author":"Fournier","year":"2020","journal-title":"J Exp Med"},{"key":"2023122911392047600_R7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s10875-018-0500-4","article-title":"Dual threat of\u00a0Epstein-Barr virus: an autopsy case report of\u00a0HIV-positive plasmablastic lymphoma complicating EBV-associated hemophagocytic lymphohistiocytosis","volume":"38","author":"Koizumi","year":"2018","journal-title":"J Clin Immunol"},{"key":"2023122911392047600_R8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jiac.2015.11.002","article-title":"Diagnostic values for\u00a0the viral load in\u00a0peripheral blood mononuclear cells of\u00a0patients with chronic active Epstein-Barr virus disease","volume":"22","author":"Ito","year":"2016","journal-title":"J Infect Chemother"},{"key":"2023122911392047600_R9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/bmt.2010.122","article-title":"Excellent outcome of\u00a0allogeneic hematopoietic SCT with reduced-intensity conditioning for\u00a0the treatment of\u00a0chronic active EBV infection","volume":"46","author":"Kawa","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"2023122911392047600_R10","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood.2020010286","article-title":"Novel somatic mutations in\u00a0UBA1 as a cause of\u00a0VEXAS syndrome","volume":"137","author":"Poulter","year":"2021","journal-title":"Blood"},{"key":"2023122911392047600_R11","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/infdis\/jiz315","article-title":"Viral DNA loads in\u00a0various blood components of\u00a0patients with Epstein-Barr virus-positive T-cell\/natural killer cell lymphoproliferative diseases","volume":"220","author":"Kawada","year":"2019","journal-title":"J Infect Dis"},{"key":"2023122911392047600_R12","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"key":"2023122911392047600_R13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12185-017-2192-6","article-title":"How we treat chronic active Epstein-Barr virus infection","volume":"105","author":"Sawada","year":"2017","journal-title":"Int J Hematol"},{"key":"2023122911392047600_R14","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in\u00a0VEXAS syndrome: insights from a retrospective series","volume":"137","author":"Bourbon","year":"2021","journal-title":"Blood"},{"key":"2023122911392047600_R15","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10081783","article-title":"Role of\u00a0proteasomes in\u00a0inflammation","volume":"10","author":"Goetzke","year":"2021","journal-title":"J Clin Med"},{"key":"2023122911392047600_R16","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study","volume":"140","author":"Heiblig","year":"2022","journal-title":"Blood"},{"key":"2023122911392047600_R17","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","article-title":"Successful allogeneic hematopoietic stem cell transplantation in\u00a0patients with VEXAS syndrome: a 2-center experience","volume":"6","author":"Diarra","year":"2022","journal-title":"Blood Adv"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxad041\/51046314\/rxad041.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/1\/199\/54920061\/rxad041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/1\/199\/54920061\/rxad041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T12:27:39Z","timestamp":1703852859000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/8\/1\/199\/7238064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,7,24]]},"published-print":{"date-parts":[[2023,12,29]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxad041","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,7,24]]}}}